MG0006 An open-label, single-arm study evaluating the activity, safety, and pharmacokinetics of rozanolixizumab in pediatric study participants with moderate to severe generalized myasthenia gravis Brief summary The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to <18 years with generalized Myasthenia Gravis (gMG). Medical Condition Generalized Myasthenia Gravis Min. Age 2 Years Max. Age 17 Years Who Can Join? All Status Recruiting Inclusion criteria - Study participant must be ≥2 to <18 years of age inclusive, at the time of signing the informed consent/assent according to local regulation - Study participant must have a documented diagnosis of generalized Myasthenia Gravis (gMG) at Screening that includes a record confirming the presence of MG specific autoantibodies to acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) prior to Screening - Study participant has Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IVa at Screening - Study participant has received existing conventional treatment(s) for gMG (eg, pyridostigmine, corticosteroids, and/or immune suppressants) prior to Screening - Study participant has had an unsatisfactory clinical response or worsening of gMG symptoms and is in need of additional therapy (for example, plasma exchange (PEX) or treatment with intravenous immunoglobulin (IVIg)) Exclusion criteria - Study participant with severe weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis at Screening or Baseline - Study participant has a known hypersensitivity to any components of the Investigational Medicinal Product (IMP) or other anti-neonatal-Fc receptor (FcRn) medications - Study participant with any active or untreated thymoma - Study participant has a history of thymectomy within 6 months prior to Screening - Study participant has a clinically relevant active infection (eg, sepsis, pneumonia, or abscess) in the opinion of the Investigator, or had a serious infection (resulting in hospitalization or requiring parenteral antibiotic treatment) within 6 weeks prior to the first dose of IMP - Study participant has received a live vaccination within 4 weeks prior to Baseline or intends to have a live vaccination during the course of the study Study Medication Description Study Medication: RYSTIGGO Other Descriptive Name: rozanolixizumab Placebo No Comparator: No Share this study Refer to a friend Via email Study Dates June 2024 Actual Start Date of Enrollment August 2026 Planned Study Completion Date General Information Study ID: MG0006 CT.gov Number: Phase: Phase 2/Phase 3 Locations Interested in our clinical studies? Just contact us Austria 金禾娱乐城Cares.AT@ucb.com +43 (0) 1 291 80 08 0800-296176 (freephone) Belgium 金禾娱乐城Cares.BE@ucb.com +32 2 559 92 00 0800 38 008 (freephone) Bulgaria 金禾娱乐城Cares.BG@ucb.com +359 2 962 9933 Canada +1 866 709 8444 Czech Republic 金禾娱乐城Cares.CZ@ucb.com +420 221 773 442 800 144 395 (freephone) Denmark 金禾娱乐城Cares.DK@ucb.com +45 32462480 80 253827 (freephone) Finland 金禾娱乐城Cares.FI@ucb.com +358 942733300 0800 9 13353 (freephone) France 金禾娱乐城Cares.FR@ucb.com +33 1 47 29 45 55 0 805 222 949 (freephone) Germany 金禾娱乐城Cares.DE@ucb.com +49 2173 48 48 48 Greece 金禾娱乐城Cares.GR@ucb.com +30 21 0997 4200 0080 012 9910 (freephone) Hungary 金禾娱乐城Cares.HU@ucb.com +36 1 472 5060 06 80 021 486 (freephone) Ireland 金禾娱乐城Cares.IE@ucb.com +353 1 463 2371 1800 93 00 75 (freephone) Italy 金禾娱乐城Cares.IT@ucb.com +39 02 3007 9300 8009-86932 (freephone) Japan Luxemburg 金禾娱乐城Cares.LU@ucb.com +32 2 559 92 12 8002 3204 (freephone) Norway 金禾娱乐城Cares.NO@ucb.com +45 32462482 800-10101 (freephone) Poland 金禾娱乐城Cares.PL@ucb.com +48 22 596 97 97 00 800 121 68 25 (freephone) Portugal 金禾娱乐城Cares.PT@ucb.com +351 213 025 300 800-8-56033 (freephone) Romania +4021 300 19 07 Slovakia 金禾娱乐城Cares.SK@ucb.com +421 2 592 020 23 0800 002 566 (freephone) Spain 金禾娱乐城Cares.ES@ucb.com +34 915 70 06 49 8000-99684 (freephone) Sweden 金禾娱乐城Cares.SE@ucb.com +45 32462481 0200 898 671 (freephone) Switzerland +41 58 822 3180 The Netherlands 金禾娱乐城Cares.NL@ucb.com +31 76 573 1130 0800 3434335 (freephone) UK 金禾娱乐城Cares.UK@ucb.com +44 1753 777 100 0800 279 3177 (freephone) USA 金禾娱乐城Cares@ucb.com +1-844-599-2273 Email Print Back to results
